| Record ID | marc_columbia/Columbia-extract-20221130-022.mrc:146084849:5163 |
| Source | marc_columbia |
| Download Link | /show-records/marc_columbia/Columbia-extract-20221130-022.mrc:146084849:5163?format=raw |
LEADER: 05163cam a2200781 a 4500
001 10772281
005 20210828224146.0
006 m o d
007 cr un||||a|a||
008 100723s2006 enka ob 001 0 eng d
035 $a(OCoLC)ocn649978215
035 $a(NNC)10772281
040 $aOCLCE$beng$epn$cOCLCE$dCOO$dOCLCQ$dE7B$dOCLCO$dOCLCF$dKNOVL$dOCLCQ$dOCLCO$dZCU$dKNOVL$dYDXCP$dOCLCQ$dBUF$dRRP$dWYU$dOCLCO$dOCLCA$dOCLCQ$dOCLCO$dHS0$dERF$dUKBTH$dLIP$dOCLCQ$dOCLCA$dOCLCQ$dOCLCA$dAGLDB$dUX1$dMM9$dOCLCQ$dLVT$dOCLCQ$dOCLCO
015 $aGBA684662$2bnb
016 7 $a013565126$2Uk
019 $a468774292$a560363707$a1066452075$a1109269502$a1112925999$a1120857775$a1146469544$a1152036995$a1159642500$a1229671420
020 $a9781628701395$q(electronic bk.)
020 $a1628701390$q(electronic bk.)
020 $a1847555306
020 $a9781847555304
020 $z9780854043705
020 $z0854043705
035 $a(OCoLC)649978215$z(OCoLC)468774292$z(OCoLC)560363707$z(OCoLC)1066452075$z(OCoLC)1109269502$z(OCoLC)1112925999$z(OCoLC)1120857775$z(OCoLC)1146469544$z(OCoLC)1152036995$z(OCoLC)1159642500$z(OCoLC)1229671420
042 $adlr
050 4 $aQP624.75.D77$bS46 2006
060 4 $a2007 A-525
060 4 $aQU 58.5$bS4795 2006
082 04 $a616.994061$222
084 $aVS 5350$2rvk
049 $aZCUA
245 00 $aSequence-specific DNA binding agents /$cedited by Michael Waring.
260 $aCambridge :$bRSC Pub.,$c©2006.
300 $a1 online resource (xi, 258 pages) :$billustrations (some color)
336 $atext$btxt$2rdacontent
337 $acomputer$bc$2rdamedia
338 $aonline resource$bcr$2rdacarrier
490 1 $aRSC biomolecular sciences
504 $aIncludes bibliographical references and index.
505 0 $aDNA recognition by triple helix formation / David A. Rusling, Tom Brown, and Keith R. Fox -- Interfacial inhibitors of human topoisomerase I / Christophe Marchand and Yves Pommier -- Diversity of topoisomerase I inhibitors for cancer chemotherapy / Nathalie Dias and Christian Bailly -- Slow DNA binding / L. Marcus Wilhelmsson, Per Lincoln, and Bengt Nordén -- DNA gene targeting using Peptide Nucleic Acid (PNA) / Peter E. Nielsen -- Actinomycin D : sixty years of progress in characterizing a sequence-selective DNA-binding agent / David E. Graves -- Thermal denaturation of drug-DNA complexes : tools and tricks / Jonathan B. Chaires and Xiaochun Shi -- Computer simulations of drug-DNA interactions : a personal journey / Federico Gago -- The discovery of G-quadruplex telomere targeting drugs / Stephen Neidle -- The mechanism of action of telomestatin, a G-quadruplex-interactive compound / Daekyu Sun and Laurence H. Hurley -- Structural features of the specific interactions between nucleic acids and small organic molecules / Alexander Serganov and Dinshaw J. Patel.
506 $3Use copy$fRestrictions unspecified$2star$5MiAaHDL
533 $aElectronic reproduction.$b[Place of publication not identified] :$cHathiTrust Digital Library,$d2010.$5MiAaHDL
538 $aMaster and use copy. Digital master created according to Benchmark for Faithful Digital Reproductions of Monographs and Serials, Version 1. Digital Library Federation, December 2002.$uhttp://purl.oclc.org/DLF/benchrepro0212$5MiAaHDL
583 1 $adigitized$c2010$hHathiTrust Digital Library$lcommitted to preserve$2pda$5MiAaHDL
588 0 $aPrint version record.
520 $aThe binding of antibiotics and drugs to DNA is a fast developing area of research with important applications in medicine, particularly the treatment of cancer. Sequence-specific DNA Binding Agents uniquely discusses key aspects of this topic, providing a novel perspective on the subject. Written by experts in the field, this book discusses diverse modes of binding of antibiotics and drugs to DNA, emphasising matters that are important or promising for cancer treatment. Chapters discuss established agents like actinomycin D but also look at novel drugs with strong potential in chemotherapy suc.
546 $aEnglish.
650 0 $aDNA-drug interactions.
650 0 $aDNA-binding proteins.
650 0 $aGene targeting.
650 0 $aDrug targeting.
650 0 $aChemotherapy.
650 12 $aDNA-Binding Proteins$xtherapeutic use.
650 22 $aChemistry, Pharmaceutical$xmethods.
650 22 $aDNA$xdrug effects.
650 22 $aDNA$xmetabolism.
650 22 $aDNA-Binding Proteins$xchemistry.
650 22 $aDNA-Binding Proteins$xmetabolism.
650 7 $aChemotherapy.$2fast$0(OCoLC)fst00853595
650 7 $aDNA-binding proteins.$2fast$0(OCoLC)fst00886613
650 7 $aDNA-drug interactions.$2fast$0(OCoLC)fst00886614
650 7 $aDrug targeting.$2fast$0(OCoLC)fst00898709
650 7 $aGene targeting.$2fast$0(OCoLC)fst00939637
655 4 $aElectronic books.
700 1 $aWaring, Michael J.
776 08 $iPrint version:$w(DLC) 2007360567$w(OCoLC)72867758
830 0 $aRSC biomolecular sciences.
856 40 $uhttp://www.columbia.edu/cgi-bin/cul/resolve?clio10772281$zACADEMIC - Pharmaceuticals, Cosmetics & Toiletries
852 8 $blweb$hEBOOKS